MET and neoplasm: Another c-MET inhibitor, Crizotinib, successfully shrunk tumours, enhanced survival, enhanced systemic and intratumoural bioavailability of gemcitabine and inhibited peritoneal dissemination in murine models of PDAC [170, 171].